請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/38126完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 郭宗甫 | |
| dc.contributor.author | Ya-Ling Chuang | en |
| dc.contributor.author | 莊雅玲 | zh_TW |
| dc.date.accessioned | 2021-06-13T16:26:44Z | - |
| dc.date.available | 2006-07-22 | |
| dc.date.copyright | 2005-07-22 | |
| dc.date.issued | 2005 | |
| dc.date.submitted | 2005-07-15 | |
| dc.identifier.citation | 行政院衛生署。87∼92年臺灣地區死亡人數按國際詳細死因與年齡、性別分 類。2004。
行政院衛生署。公告衛生署審核通過之健康食品一覽表。2004。 行政院衛生署。國人尿酸的平均值、標準差、過高比率依性別、年齡層之比較。 行政院衛生署中醫藥委員會。台灣常用藥用植物圖鑑第一冊。102,2002。 吳煥、顧冠彬。台灣抗痛風草藥(摘要)。台灣草藥新知系列講座。http://snipurl.com/f5x4。2003。 沈永紹。獸醫實驗診斷學提要,53,202-204,258-261,華香園出版社,台北,1982。 國人高血壓、糖尿病、高尿酸血症之現況(性別、年齡、地區別、原住民身分)。2003。 郭宗甫、劉朝鑫。Pyrimethamine對大白鼠及雞胚胎致畸形性之研究。國立台灣大學農學院研究報告。34: 305-334,1994。 郭宗甫。pyrimethamine對大白鼠及雞胚胎致畸形性之研究。國立台灣大學獸醫學研究所博士論文。1989。 楊恭毅。單子葉植物。楊氏園藝植物大名典。6846,1984。 Agudelo CA and Wise C. Crystal-associated arthritis. Clin Geriatr Med 14: 495-513, 1998. Ames BN, Mccann J, Yamasaki E. Methods for detecting carcinogens and mutagens with the Salmonella/mammalian-microsome mutagenicity test. Mutat Res 6: 347-364, 1975. Anker SD, Doehner W, Rauchhaus M, Sharma R, Francis D, Knosalla C, Davos CH, Cicoira M, Shamim W, Kemp M, Segal R, Osterziel KJ, Leyva F, Hetzer R, Ponikowski P, Coats AJ. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 107: 1991-1997, 2003. Bannister P. Winter frost resistance of leaves of some plants growing in Dunedin, New Zealand, in winter 1985. N Z J Bot 24: 505-507, 1986. Barrow MV and Taylor WJ. A rapid method for detecting malformations in rat fetuses. J Morphol 127: 291-305, 1969. Beckman JS and Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 271: C1424-1437, 1996. Bendayan D, Shitrit D, Ygla M, Huerta M, Fink G, Kramer M. Hyperuricemia as a prognostic factor in pulmonary arterial hypertension. Respir Med 97: 130-133, 2003. Berger L and Yu TF. Renal function in gout. IV. An analysis of 524 gouty subjects including long-term follow-up studies. Am J Med 59: 605-613, 1975. Bruder G, Heid H, Jarasch ED, Keenan TW, Mather IH. Characteristics of membrane-bound and soluble forms of xanthine oxidase from milk and endothelial cells of capillaries. Biochim Biophys Acta 701: 357-369, 1982. Buehler E. Delayed contact hypersensitivity in the guinea pig. Arch Dermatol 91: 171-177, 1965. Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med 82: 421-426, 1987. Candan F. Effect of Rhus coriaria L. (Anacardiaceae) on superoxide radical scavenging and xanthine oxidase activity. J Enzyme Inhib Med Chem 18: 59-62, 2003. Center for Drug Evaluation and Research. Single Dose Acute Toxicity Testing for Pharmaceuticals. Guidance for Industry 1996. Chang SJ, Ko YC, Wang TN, Chang FT, Cinkotai FF, Chen CJ. High prevalence of gout and related risk factors in Taiwan's Aborigines. J Rheumatol 24: 1364-1369, 1997. Chen J, He J, Hamm L, Batuman V, Whelton PK. Serum antioxidant vitamins and blood pressure in the United States population. Hypertension 40: 810-816, 2002. Chen TJ and Yu BT. Report on survey of serum glucose, cholesterol, uric acid and creatinine values in adults of Taipei city. J Nephrol 9: 109-118, 1995. Chiang LC, Cheng HY, Liu MC, Chiang W, Lin CC. In vitro anti-herpes simplex viruses and anti-adenoviruses activity of twelve traditionally used medicinal plants in Taiwan. Biol Pharm Bull 26: 1600-1604, 2003. Choi HS, Song HS, Ukeda H, Sawamura M. Radical-Scavenging Activities of Citrus Essential Oils and Their Components: Detection Using 1,1-Diphenyl-2-picrylhydrazyl. J Agric Food Chem 48: 4156-4161, 2000. Chou C. Hyperuricemia and gout among Taiwan Aborigines and Taiwanese-prevalence and risk factors. Chin Med J (Engl) 116: 965-967, 2003. Chou CT and Lai JS. The epidemiology of hyperuricaemia and gout in Taiwan aborigines. Br J Rheumatol 37: 258-262, 1998. Chou P, Soong LN, Lin HY. Community-based epidemiological study on hyperuricemia in Pu-Li, Taiwan. J Formos Med Assoc 92: 597-602, 1993. Cohen G. Enzymatic/nonenzymatic sources of oxyradicals and regulation of antioxidant defenses. Ann N Y Acad Sci 738: 8-14, 1994. Cragg GM, Newman DJ, Snader KM. Natural Products in Drug Discovery and Development. J Nat Prod 60: 52-60, 1997. Dincer H, Dincer A, Levinson D. Asymptomatic hyperuricemia: to treat or not to treat. Cleve Clin J Med 69: 594, 597, 600-2 passim, 2002. Dunn BJ. Toxicology of the Eye. CRC Handbook of Toxicology 1995. Emmerson B. Hyperlipidaemia in hyperuricaemia and gout. Ann Rheum Dis 57: 509-510, 1998. Emmerson BT. The management of gout. N Engl J Med 445-451, 1996. Feher M, Hepburn A, Hogarth M, Ball S,Kaye S. Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout. Rheumatology (Oxford) 42: 321-325, 2003. Forman HJ and Torres M. Redox signaling in macrophages. Mol Aspects Med 22: 189-216, 2001. Friedl HP, Till GO, Trentz O, Ward PA. Role of oxygen radicals in tourniquet-related ischemia-reperfusion injury of human patients. Klin Wochenschr 69: 1109-1112, 1991. Galvan AQ, Natali A, Baldi S, Frascerra S, Sanna G, Ciociaro D, Ferrannini E. Effect of insulin on uric acid excretion in humans. Am J Physiol 268: E1-5, 1995. Garcia-Pavia P, Torres R, Rivero M, Ahmed M, Garcia-Puig J, Becker M. Phosphoribosylpyrophosphate synthetase overactivity as a cause of uric acid overproduction in a young woman. Arthritis Rheum 48: 2036-2041, 2003. Gavin A and Struthers A. Hyperuricemia and adverse outcomes in cardiovascular disease: potential for therapeutic intervention. Am J Cardiovasc Drugs 3: 309-314, 2003. Gertler MM, Garn SM, Levine SA. Serum uric acid in relation to age and physique in health and in coronary heart disease. Ann Intern Med 34: 1421-1431, 1951. Govindarajan R, Rastogi S, Vijayakumar M, Shirwaikar A, Rawat AK, Mehrotra S, Pushpangadan P. Studies on the antioxidant activities of Desmodium gangeticum. Biol Pharm Bull 26: 1424-1427, 2003. Govindarajan R, Vijayakumar M, Rao CV, Shirwaikar A, Rawat AK, Mehrotra S, Pushpangadan P. Antioxidant potential of Anogeissus latifolia. Biol Pharm Bull 27: 1266-1269, 2004. Granger DN, Hollwarth ME, Parks DA. Ischemia-reperfusion injury: role of oxygen-derived free radicals. Acta Physiol. Scand. 548: 47-63, 1986. Gresser U, Gathof B, Zollner N. Uric acid levels in southern Germany in 1989. A omparison with studies from 1962, 1971, and 1984. Klin Wochenschr 68: 222-1228, 1990. Harrison R. Structure and function of xanthine oxidoreductase: where are we now? Free Radic Biol Med 33: 774-797, 2002. Hoffmann H and Speit G. Assessment of DNA damage in peripheral blood of heavy smokers with the comet assay and the micronucleus test. Mutat Res 581: 105-114, 2005. http://snipurl.com/ex69 ICH. Guideline on the need for carcinogenicity studies of pharmaceuticals. ICH harmonised tripartite guidel, 1995. ICH. International Conference an Harmonization Topic M3 Document. “Guideline for the timing of non-clinical safety studies for the conduct of human clinical trials for pharmaceuticals” , 1998. Inokuchi T, Moriwaki Y, Takahashi S, Tsutsumi Z, Ka T, Yamamoto A, Cheng J, Hashimoto-Tamaoki T, Hada T, Yamamoto T. Identification of a new point mutation in hypoxanthine phosphoribosyl transferase responsible for hyperuricemia in a female patient. Metabolism 53: 1500-1502, 2004. Ishibuchi S, Morimoto H, Oe T, Ikebe T, Inoue H, Fukunari A, Kamezawa M, Yamada I, Naka Y. Synthesis and structure-activity relationships of 1-phenylpyrazoles as xanthine oxidase inhibitors. Bioorg Med Chem Lett 11: 879-882, 2001. Jagetia GC and Baliga MS. Treatment with Alstonia scholaris enhances radiosensitivity in vitro and in vivo. Cancer Biother Radiopharm 18: 917-929, 2003. Jiang WL, Luo XL, Kuang SJ. Effects of Alternanthera philoxeroides Griseb against dengue virus in vitro.Di Yi Jun Yi Da Xue Xue Bao 25: 454-456, 2005. Johnson WJ, Stavric B, Chartrand A. Uricase inhibition in the rat by s-triazines: an animal model for hyperuricemia and hyperuricosuria. Proc Soc Exp Biol Med 131: 8-12, 1969. Kahn AM. Indirect coupling between sodium and urate transport in the proximal tubule. Kidney Int 36: 378-84, 1989. Kang D, Nakagawa T, Feng L, Watanabe S, Han L, Mazzali M, Truong L, Harris R, Johnson R. A role for uric acid in the progression of renal disease. J Am Soc Nephrol 13: 2888-2897, 2002. Kawaguchi T, Shimode M, Matsushita H, Nagase S. Sex differences in the effect of uric acid on the survival of analbuminemic rats exposed to cold: effects of gonadal hormones and uric acid. Jpn J Physiol 37: 941-945, 1987. Kelly D and Skipworth JP. Tradescantia fluminensis in a Manawatu (New Zealand) forest: growth and effects on regeneration. N Z J Bot 22: 393-397, 1984. Kerr ME, Bender CM, Monti EJ. An introduction to oxygen free radicals. Heart Lung 25: 200-9; quiz 210-211, 1996. Kissau L, Stahl P, Mazitschek R, Giannis A, Waldmann H. Development of natural product-derived receptor tyrosine kinase inhibitors based on conservation of protein domain fold. Med Chem 46: 2917-2931, 2003. Klemp P, Stansfield SA, Castle B, Robertson MC.Gout is on the increase in New Zealand. Ann. Rheum. Dis 56: 22-26,1997. Ko Y, Wang T, Tsai L, Chang F, Chang S. High prevalence of hyperuricemia in adolescent Taiwan aborigines. J Rheumatol 29: 837-842, 2002. Kohen R and Nyska A. Oxidation of biological systems: oxidative stress phenomena, antioxidants, redox reactions, and methods for their quantification. Toxicol Pathol 30: 620-650, 2002. Kohen R. Skin antioxidants: their role in aging and in oxidative stress--new approaches for their evaluation. Biomed Pharmacother 4: 181-192, 1999. Kong L, Wolfender J, Cheng C, Hostettmann K, Tan R. Xanthine oxidase inhibitors from Brandisia hancei. Planta Med 65: 744-746, 1999. Kong L, Zhou J, Wen Y, Li J, Cheng CH. Aesculin possesses potent hypouricemic action in rodents but is devoid of xanthine oxidase/dehydrogenase inhibitory activity. Planta Med 68: 175-178, 2002. Kong LD, Cai Y, Huang WW, Cheng CH, Tan RX. Inhibition of xanthine oxidase by some Chinese medicinal plants used to treat gout. J Ethnopharmacol 73: 199-207, 2000a. Kong LD, Zhang Y, Pan X, Tan RX, Cheng CH. Inhibition of xanthine oxidase by liquiritigenin and isoliquiritigenin isolated from Sinofranchetia chinensis. Cell Mol Life Sci 57: 500-505, 2000b. Kramer HM and Curhan G. The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988-1994. Am J Kidney Dis 40: 37-42, 2002. Kuhn MA. Oxygen free radicals and antioxidants. Am J Nurs 4: 58-62, 2003. Kuo TP. Gout in the tropical Taiwan. Tsa Chih Gaoxiong Yi Xue Yuan Tong Xue Hui 63: 415-426, 1964. Lai S, Li T, Ng K. Hyperuricaemia and its related factors in Taiwanese middle-aged adults. Int J Nurs Pract 8: 56-60, 2002. Langford HG, Blaufox MD, Borhani NO, Curb JD, Molteni A, Schneider KA, Pressel S. Is thiazide-produced uric acid elevation harmful? Analysis of data from the Hypertension Detection and Follow-up Program. Arch Intern Med 147: 645-649, 1987. Lee JY, Hwang WI, Lim ST. Antioxidant and anticancer activities of organic extracts from Platycodon grandiflorum A. De Candolle roots. J Ethnopharmacol 93: 409-415, 2004. Lee KJ and Jeong HG. Protective effect of Platycodi radix on carbon tetrachloride-induced hepatotoxicity. Food Chem Toxicol 40: 517-525, 2002. Lee W, Chen H, Wang W, Wei P, Lin C, Huang M. Metabolic syndrome in obese patients referred for weight reduction surgery in Taiwan. J Formos Med Assoc 102: 459-464, 2003. Lin KC, Lin HY, Chou P. Community based epidemiological study on hyperuricemia and gout in Kin-Hu, Kinmen. J Rheumatol 27: 1045-1050, 2000. MacNee W. Oxidants/antioxidants and chronic obstructive pulmonary disease: pathogenesis to therapy. Novartis Found Symp 234: 169-85, 2001. Malaviya AN, Al-Ali N, Sharma P, Al-Sughayer A, Umamaheswaran I, Al-Gaurer S, Hussain AAA. Prevalence of Hyperuricaemia among kuwaitis possibly without a proportionate increase in gout. Br J Rheumatol 36: 405, 1997. Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, Lan HY, Kivlighn S, Johnson RJ. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 38: 1101-1106, 2001. Mazzali M, Kanellis J, Han L, Feng L, Xia Y, Chen Q, Kang D, Gordon K, Watanabe S, Nakagawa T, Lan H, Johnson R. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 282: F991-997, 2002. Messerli FH, Frohlich ED, Dreslinski GR, Suarez DH, Aristimuno GG. Serum uric acid in essential hypertension: an indicator of renal vascular involvement. Ann Intern Med 93: 817-821, 1980. Naito S, Nishimura M, Nogawa H. Pharmacokinetics of BOF-4272, a xanthine oxidase inhibitor, after single intravenous or oral administration to male mice and rats. J Pharm Pharmacol 51: 347-351, 1999. Nakagawa T, Mazzali M, Kang D, Kanellis J, Watanabe S, Sanchez-Lozada L, Rodriguez-Iturbe B, Herrera-Acosta J, Johnson R. Hyperuricemia causes glomerular hypertrophy in the rat. Am J Nephrol 23: 2-7, 2003. Nakanishi T, Nishi M, Inada A, Obata H, Tanabe N, Abe S, Wakashiro M. Two new potent inhibitors of xanthine oxidase from leaves of Perilla frutescens Britton var. acuta Kudo. Chem Pharm Bull 38: 1772-1774, 1990. Nguyen MTT, Awale S, Tezuka Y, Tran QL, Watanabe H, Kadota S. Xanthine oxidase inhibitory activity of Vietnamese medicinal plants. Biol Pharm Bull 27: 1414-1421, 2004. Nieto FJ, Iribarren C, Gross M, Comstock GW, Cutler RG. Uric acid and serum antioxidant capacity: a reaction to atherosclerosis? Atherosclerosis 148: 131-139, 2000. Osada Y, Tsuchimoto M, Fukushima H, Takahashi K, Kondo S, Hasegawa M, Komoriya K. Hypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodents. Eur J Pharmacol 241: 183-188, 1993. Osawa T and Namiki M. A novel type of antioxidant isolated from leaf wax of Eucalyptus leaves. Agric Biol Chem 45: 735-740, 1981. Owen PL and Johns T. Xanthine oxidase inhibitory activity of northeastern North American plant remedies used for gout. J Ethnopharmacol 64: 149-160, 1999. PDR. Physicians’ desk reference® Medical Economics Co, USA, 1224-1226, 2001. Perkins P and Jones AC. Gout. Ann Rheum Dis 10: 611-617, 1999. Proudlock R, Thompson C, Longstaff E. Examination of the potential genotoxicity of pure capsaicin in bacterial mutation, chromosome aberration, and rodent micronucleus tests. Environ Mol Mutagen 44: 441-447, 2004. Puig J and Ruilope L. Uric acid as a cardiovascular risk factor in arterial hypertension. J Hypertens 17: 869-872, 1999. Rachel S. Tradescantia fluminensis (herb). http://snipurl.com/f5lj, 2004. Raju K, Anbuganapathi G, Gokulakrishnan V, Rajkapoor B, Jayakar B, Manian S. Effect of dried fruits of Solanum nigrum LINN against CCl4-induced hepatic damage in rats. Biol Pharm Bull 26: 1618-1619, 2003. Richard SS. Clinical and functional histology for medical students. Nan sang tang publishing company, Taiwan, 7-10, 1984. Roch-Ramel F and Weiner IM. Renal excretion of urate: factors determining the actions of drugs. Kidney Int 18: 665-676, 1980. Rodrigues MR, Rodriguez D, Russo M, Campa A. Macrophage activation includes high intracellular myeloperoxidase activity. Biochem Biophys Res Commun 292: 869-873, 2002. Rott KT and Agudelo CA. Gout. JAMA 289: 2857-2860, 2003. Samee W, Sae-Lee N, Ungwitayatorn J. Structure-radical scavenging activity relationships of the synthesized chromone derivatives. SWU J Pharm Sci 9: 36-42, 2004. Sampson L, Rimm E, Hollman PC, de Vries JH, Katan MB. Flavonol and flavone intakes in US health professionals. J Am Diet Assoc 102: 1414-1420, 2002. Sánchez I, Gomez-Garibay F, Taboada J, Ruiz BH. Antiviral effect of flavonoids on the dengue virus. Phytother Res 14: 89-92, 2000. Sanchez-Lozada LG, Tapia E, Santamaria J, Avila-Casado C, Soto V, Nepomuceno T, Rodriguez-Iturbe B, Johnson RJ, Herrera-Acosta J. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int 1: 237-247, 2005. Scheibmeir HD, Christensen K, Whitaker SH, Jegaethesan J, Clancy R, Pierce JD. A review of free radicals and antioxidants for critical care nurses. Intensive Crit Care Nurs 21: 24-28, 2005. Selby JV, Friedman GD, Quesenberry CP Jr. Precursors of essential hypertension: pulmonary function, heart rate, uric acid, serum cholesterol, and other serum chemistries. Am J Epidemiol 131:1017-1027, 1990. Singer JZ and Wallace SL. The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality. Arthritis Rheum 29: 82-87, 1986. Sircar S, Keyvani-Amineh H, Weber JM. Inhibition of adenovirus infection with protease inhibitors. Antiviral Res 30: 147-153, 1996. Stefanova Z, Neychev H, Ivanovska N, Kostova I. Effect of a total extract from Fraxinus ornus stem bark and esculin on zymosan- and carrageenan-induced paw oedema in mice. J Ethnopharmacol 46: 101-106,1995. Sumi S and Wada Y. Xanthine oxidase (xanthine dehydrogenase). Nippon Rinsho 12: 3226-3229, 1996. Sweeney AP, Wyllie SG, Shalliker RA,Markham JL. Xanthine oxidase inhibitory activity of selected Australian native plants. J Ethnopharmacol 75: 273-277, 2001. Takahashi S, Moriwaki Y, Yamamoto T, Tsutsumi Z, Ka T, Fukuchi M. Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism. Ann Rheum Dis 6: 572-575, 2003. Tsai WL, Yang CY, Lin SF, Fang FM. Impact of obesity on medical problems and quality of life in Taiwan. Am J Epidemiol 160: 557-565, 2004. Unno T, Sugimoto A, Kakuda T. Xanthine oxidase inhibitors from the leaves of Lagerstroemia speciosa (L.) Pers. J Ethnopharmacol 93: 391-395, 2004. Wang WH, Chang SJ, Wang TN, Cheng LS, Feng YP, Chen CJ, Huang CH, Ko YC. Complex segregation and linkage analysis of familial gout in Taiwanese aborigines. Arthritis Rheum 50: 242-246, 2004. Waring WS, Adwani SH, Breukels O, Webb DJ, Maxwell SR. Hyperuricaemia does not impair cardiovascular function in healthy adults. Heart 90: 155-159, 2004. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, Boffey SJ, Valentine PJ, Curwen JO, Musgrove HL, Graham GA, Hughes GD, Thomas AP, Stokes ES, Curry B, Richmond GH, Wadsworth PF, Bigley AL, Hennequin LF. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 62: 4645-4655, 2002. Wortmann RL and Kelley WN. Gout and Hyperuricemia. In: Shaun R ed. Kelley’s textbook of rheumatology. 6th ed. W.B. Saunders Co, Philadelphia, 1315, 1348-1353, 2001. Wu XW, Muzny DM, Lee CC, Caskey CT. Two independent mutational events in the loss of urate oxidase during hominoid evolution. J Mol Evol 34: 78-84, 1992. Yamada H, Kotaki H, Furitsu H, Sawada Y,Iga T. Mechanism of the uricosuric action of the anti-inflammatory drug E3040 used to treat inflammatory bowel disease I: study using a rat model of hyperuricemia. Biopharm Drug Dispos 20: 77-83, 1999. Yang ZQ, Zhang MY, Liu JJ, Hu ZJ, Zhu BL, Liu YW, Wang GZ, Wan M, Wu XL. Extraction of effective parts of Alternanthera philoxeroides (Mart.) Griseb. and its antiviral effect. Zhongguo Zhong Yao Za Zhi 14: 488-490, 511-512, 1989. Zhu JX, Wang Y, Kong LD, Yang C, Zhang X. Effects of Biota orientalis extract and its flavonoid constituents, quercetin and rutin on serum uric acid levels in oxonate-induced mice and xanthine dehydrogenase and xanthine oxidase activities in mouse liver. J Ethnopharmacol 93: 133-140, 2004. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/38126 | - |
| dc.description.abstract | 血中尿酸值會藉由尿酸的過度製造或排泄過低而增高,並造成高尿酸血症(hyperuricemia)。高尿酸血症的發生,可能引起尿酸鹽沈積於關節而引發疼痛性炎症反應而造成痛風,且已有許多報告指出其和動脈硬化、高血壓、心血管疾病、糖尿病及腎臟疾病相關。黃嘌呤酶會將次黃嘌呤及黃嘌呤代謝成尿酸,故其為引發高尿酸血症之關鍵酵素。活性氧屬除已知會造成脂質過氧化而導致食物變性外,也有許多文獻指出其與慢性心衰竭、老化及呼吸性窘迫症候群有關。而由於藥品使用的副作用及保健食品的盛行,使得自天然物中找尋無副作用或副作用較低的有效成分之研究受到重視,其中又以黃嘌呤酶抑制劑及抗氧化劑等為目前研究重心。而雖然大部分的天然物是安全的,但長期性且大量的服用是否會影響肝腎功能,或懷孕動物高劑量的服用是否會影響胚胎發育或導致胎兒畸形,仍須實驗進行探究。因此本實驗選用傳統中醫藥用於降低血中尿酸值之植物白花水竹草,進行其萃取物之生物活性試驗及毒性試驗。
新鮮白花水竹草降低血中尿酸值試驗是使用尿酸酶抑制劑oxonate,以腹腔注射方式製成高尿酸血症模式大鼠,在分別口服白花水竹草之葉粗萃液、莖粗萃液或磷酸緩衝液後,每隔90分鐘採取血液進行血液學及血液生化學檢測,並同時監測血壓變化。萃取物降低血中尿酸值試驗是使用高尿酸血症模式大鼠,分別口服由白花水竹草乾燥葉片以正己烷、乙醯乙脂、丁醇及蒸餾水所萃取出之HE、EAE、BE及WE產物,並每隔30分鐘採血進行尿酸值檢測。促尿酸排泄試驗以高尿酸血症模式大鼠,分別口服磷酸緩衝液或WE產物,並於口服後之30、90、150及210分鐘採取尿液,進行尿酸值檢測。DPPH自由基清除效力及抗氧化活性試驗是以不同濃度的四種分劃層萃取物與試劑反應後,分別於517 nm及500 nm進行吸光值檢測。另外分別於懷孕第1~4天或8~11天口服50倍降低血中尿酸值之有效劑量的白花水竹草乾葉(625 mg/kg),以瞭解其是否影響胎兒著床及致畸形。亞急性毒性試驗則連續28天使大鼠口服10倍降低血中尿酸值之有效劑量的白花水竹草乾葉(125 mg/kg),並以血液學、血液生化學及組織病理學評估毒性。 研究結果顯示新鮮白花水竹草葉片可降低血中尿酸值,其四種分劃層萃取產物也具同樣效果,且最後一個評估時間點以WE之降低血中尿酸值能力最佳。四種分劃層萃取產物也可抑制黃嘌呤酶,且同樣以WE之抑制力最強。促尿酸排泄試驗結果顯示WE無促進尿酸排泄效力。DPPH自由基清除試驗及抗氧化活性試驗,則以BW之抗氧化力最強。毒性試驗方面,結果顯示懷孕期間口服50倍降低血中尿酸值之白花水竹草乾葉不會造成懷孕母鼠之胚胎著床、致畸形性及耗損等影響;亞急性毒性試驗之血液學檢測結果顯示Hb、HCT及RBC值顯著上升(p<0.05),血液生化學檢測結果顯示ALKP及BUN值顯著下降(p<0.05)。組織病理學檢查結果顯示肝細胞腫脹及輕微膽管增生,其餘肺臟、脾臟及腎臟則無顯著變化。 綜合本研究之實驗結果,可以得到以下結論:白花水竹草可藉由抑制黃嘌呤酶而降低血中尿酸值,且可清除自由基及預防脂質過氧化而達抗氧化之功能。雖懷孕期間口服五十倍降低血中尿酸值劑量之白花水竹草並不會影響懷孕母鼠之著床,也不會造成胎仔出現畸形或耗損之情形,但28天且高量的口服白花水竹草會造成肝細胞腫脹及輕微膽管增生情形,表示白花水竹草也許不適合長期且大量的服用。 | zh_TW |
| dc.description.abstract | Serum uric acid was be elevated because of urate overproduction and/or underexcretion, and it will cause hyperuricemia. Hyperuricemia may cause the deposition of uric acid in joints and lead to painful inflammation. There were also many researches indicated that hyperuricemia was related with atherosclerosis, hypertension, cardiovascular diseases, diabetes mellitus and renal disease. Xanthine oxidase (XO) will catalyze the hypoxanthine and xanthine to uric acid, which is the main enzyme in hyperuricemia. The current agent used to treat the hyperuricemia is XO inhibitor, but the allopurinol used in clinical will cause side effect and prompt the development of XO inhibitor. Reactive oxygen species (ROS) had been known to cause lipid peroxidation which induce nutritional degradation of food products. ROS were also related to chronic cardiac failure, ageing, acute respiratory distress syndrome. Because of the side effect of the medicine and the fashion of healthy food, many scholars start to pay attention to the research of non side effect or low side effect compound from traditional medicine. Among these researches, most scholars are focusing on XO inhibitor agents and antioxidant. Although the natural antioxidant is safe in general, daily usage may cause potential complication, for example it may affect the function of liver and kidney or it may also impact on fertilized egg implantation and fetal organogenesis when the rats were oral administration with high dosage during the period of pregnancy. Therefore this study was investigated to the bioactivity and toxicity of extractive from the leaves of Tradescantia albiflora Kunth, which is a Chinese medicine plant to reduce serum uric acid level on rat.
The experiment was designed to use oxonate to be injected intraperitonelly to induce rat in hyperuricemic model, then these rats were oral administration crude extractive from the leaves, stem of T. albiflora or PBS respectively. Blood samples were collected to process hematology and biochemistry study every 90 mins, and monitored the change of blood pressure in the same time. We have used hexane, ethyl acetate, butanol and distilled water to extract the dry leaves of T. albiflora then got hexane extractive (HE), ethyl acetate extractive (EAE), butanol extractive (BE) and water extractive (WE) respectively. The experiment of decrease the plasma uric acid (PUA) level with extractives used by rat in hyperuricemic model to oral administration with HE, EAE, BE and WE extractive respectively, and bloods samples were collected to process PUA test every 30 mins. The experiments of eliminated uric acid were utilized by rat in hyperuricemic model to oral administration with the PBS or WE respectively, and urine samples were collected to process urine uric acid (UUA) test after 30、90、150 and 210 mins. These tests of the efficiency for scavenge of DPPH and the ferric thiocyanate (FTC) have utilized different concentration of extractives belonging to 4 layers react with agents, and tested the absorption with 517 and 500 nm respectively. Crude extractives were divided into three groups. One was the control group (oral phosphate buffer). Second group was tested for oral consumption of 50 times the effective dosage of reducing plasma uric acid level (625 mg/kg) for 1~4 days during pregnancy. Third group was tested during 8~11 days of pregnancy. Subacute toxicities were tested the consumption of the 10 times effective dosage of reducing plasma uric acid level (125 mg/kg) for 28 days and blood samples were collected to be conducted hematology, biochemistry and histology study. The results of these studies indicated that T. albiflora can decrease the level of blood uric acid, these 4 different types of extractive had the same ability, but the WE had the best affect in last estimative point (240 min). These 4 different types of extractive can also inhibit the XO, and WE had the best efficacy. The result of eliminated uric acid test revealed that WE hadn’t affect to eliminate uric acid. The BE had better efficacy in the scavenge of DPPH testing and the FTC testing. The toxicological result showed that fertilized egg implantation rate, fetal organogenesis and resorption rate were not be impacted on the femate rat after oral administrateion with 50 times the effective dosage extractives of reducing plasma uric acid level (625 mg/kg) from the leaves of T. albiflora extractive during the pregnant period.The test of subacute toxicity revealed the Hb, HCT and RBC had significant increase (p<0.05); the ALKP and BUN had significant decrease (p<0.05) compared with control group. This study has shown that T. albiflora can decrease the blood uric acid by inhibiting XO, and it also can eliminate free radical by preventing fatty oxidantion to achieve antioxidant. Female rat oral administrated high dosage during the period of pregnancy may not impact fertilized egg implantation, fetal organogenesis and resorption, but oral administrated T. albiflora for long and high dosage may cause hepatic cell swelling and slightly hyperplasia of bile duct, it could suggest that T. albiflora is not suitable to medicate in long and high dosage. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-13T16:26:44Z (GMT). No. of bitstreams: 1 ntu-94-R92629018-1.pdf: 2148287 bytes, checksum: f1f997f80498983a72f53120aa0167e7 (MD5) Previous issue date: 2005 | en |
| dc.description.tableofcontents | 英文縮寫對照表---------------------------------------------------------------------------------I
目錄----------------------------------------------------------------------------------------------III 圖次---------------------------------------------------------------------------------------------VII 表次--------------------------------------------------------------------------------------------XIII 中文摘要--------------------------------------------------------------------------------------XIX 英文摘要--------------------------------------------------------------------------------------XXI 第一章 文獻回顧------------------------------------------------------------------------------1 第一節 白花水竹草介紹---------------------------------------------------------------1 1.1 學名------------------------------------------------------------------------------1 1.2 原產地及用途-------------------------------------------------------------------2 第二節 尿酸與高尿酸血症------------------------------------------------------------2 2.1 尿酸生合成---------------------------------------------------------------------2 2.2 高尿酸血症原因---------------------------------------------------------------4 2.3 高尿酸血症與疾病------------------------------------------------------------5 2.3.1 高尿酸血症與痛風----------------------------------------------------5 2.3.2 高尿酸血症與心血管疾病-------------------------------------------6 2.3.3 高尿酸血症與腎臟傷害----------------------------------------------6 2.3.4 高尿酸血症與其他疾病----------------------------------------------7 2.4 高尿酸血症及痛風流行病學調查------------------------------------------7 2.4.1 台灣人高尿酸血症及痛風流行病學調查-------------------------7 2.4.2 其他地區高尿酸血症及痛風流行病學調查----------------------9 2.5 高尿酸血症治療---------------------------------------------------------------9 2.5.1 尿酸生成抑制劑-------------------------------------------------------9 2.5.2 尿酸排泄促進劑-----------------------------------------------------10 2.6 黃嘌呤酶抑制劑之天然物-------------------------------------------------11 2.7 高尿酸血症動物模式-------------------------------------------------------12 2.8 黃嘌呤酶之特性-------------------------------------------------------------13 2.9 黃嘌呤酶缺血再灌流傷害之關係----------------------------------------13 第三節 活性氧-------------------------------------------------------------------------14 3.1 活性氧的定義----------------------------------------------------------------14 3.2 活性氧種類-------------------------------------------------------------------15 3.3 活性氧來源-------------------------------------------------------------------18 3.4 體內抗氧化機制-------------------------------------------------------------19 3.5 抗氧化活性測定-------------------------------------------------------------20 3.6 應用於抗氧化之天然物----------------------------------------------------21 第四節 毒性評估----------------------------------------------------------------------21 4.1 毒性試驗項目----------------------------------------------------------------21 4.2 臨床毒性試驗時機----------------------------------------------------------24 第二章 緒言----------------------------------------------------------------------------------26 第三章 材料與方法-------------------------------------------------------------------------28 第一節 白花水竹草樣本製備-------------------------------------------------------28 1.1 白花水竹草粗萃液之製備-------------------------------------------------28 1.2 白花水竹草成分之製備----------------------------------------------------28 第二節 高尿酸血症動物模式建立-------------------------------------------------29 2.1 實驗動物----------------------------------------------------------------------29 2.2 頸動脈埋管操作-------------------------------------------------------------29 2.3 實驗設計----------------------------------------------------------------------30 2.4 高尿酸血症模式大鼠之操作----------------------------------------------30 2.5 血漿採集方法----------------------------------------------------------------31 2.6 資料分析與統計-------------------------------------------------------------31 第三節 高尿酸血症模式大鼠研究白花水竹草降低血中尿酸值效力試驗-31 3.1 新鮮植物效力試驗----------------------------------------------------------31 3.2 成分效力試驗----------------------------------------------------------------32 3.3 抽離成分促進尿酸排泄試驗----------------------------------------------33 3.4 資料分析與統計-------------------------------------------------------------33 第四節 生物活性篩選---------------------------------------------------------------33 4.1 黃嘌呤酶抑制試驗----------------------------------------------------------33 4.2 自由基2,2-Diphenyl-1-picrylhydrazyl(DPPH)清除能力----------34 4.3 抗氧化性測定----------------------------------------------------------------35 第五節 高劑量白花水竹草對大鼠毒理學之探討-------------------------------35 5.1 白花水竹草對懷孕大鼠受精卵著床之影響----------------------------35 5.2 白花水竹草對懷孕大鼠致畸形性試驗----------------------------------36 5.3 亞急性毒性試驗-------------------------------------------------------------36 5.4 組織病理學檢查-------------------------------------------------------------37 5.5 資料分析與統計-------------------------------------------------------------37 第四章 結果----------------------------------------------------------------------------------38 第一節 白花水竹草樣本製備------------------------------------------------------38 1.1 白花水竹草乾濕比----------------------------------------------------------38 1.2 白花水竹草各層萃取成分比例-------------------------------------------38 第二節 高尿酸血症動物模式建立------------------------------------------------38 2.1 高尿酸血症模式大鼠的建立----------------------------------------------38 2.2 新鮮白花水竹草降低血中尿酸值效力結果----------------------------39 2.3 新鮮白花水竹草對高尿酸血症模式大鼠各組血液學檢測結果----39 2.4 新鮮白花水竹草對高尿酸血症模式大鼠各組血液化學檢測結果-41 2.5 新鮮白花水竹草對高尿酸血症模式大鼠各組血壓檢測結果-------42 2.6 萃取成分降低血中尿酸值效力結果-------------------------------------43 2.7 抽離成分促尿酸排泄作用-------------------------------------------------44 第三節 生物活性篩選結果---------------------------------------------------------44 3.1 黃嘌呤酶抑制試驗----------------------------------------------------------44 3.2 自由基2,2-Diphenyl-1-picrylhydrazyl(DPPH)清除能力----------45 3.3 抗氧化性測定----------------------------------------------------------------45 第四節 高劑量白花水竹草對懷孕大鼠毒理學之探討------------------------46 4.1 白花水竹草對懷孕大鼠受精卵排卵及著床之影響------------------46 4.2 白花水竹草對懷孕大鼠致畸形性之影響------------------------------46 4.3 亞急性毒性試驗------------------------------------------------------------46 4.3.1 組織病理學檢查------------------------------------------------------47 第五章 討論----------------------------------------------------------------------------------48 第六章 參考文獻----------------------------------------------------------------------------52 附錄----------------------------------------------------------------------------------------------64 | |
| dc.language.iso | zh-TW | |
| dc.subject | 抗氧化劑 | zh_TW |
| dc.subject | 高尿酸血症 | zh_TW |
| dc.subject | 黃嘌呤酶 | zh_TW |
| dc.subject | 抑制劑 | zh_TW |
| dc.subject | 白花水竹草 | zh_TW |
| dc.subject | xanthine oxidase inhibitor | en |
| dc.subject | Tradescantia albiflora Kunth | en |
| dc.subject | antioxidant | en |
| dc.subject | hyperuricemia | en |
| dc.title | 白花水竹草(Tradescantia albiflora Kunth)降低大鼠血中
尿酸值、抗氧化性及其毒性探討 | zh_TW |
| dc.title | The Study of Chinese Medicinal Herb Tradescantia albiflora Kunth on Rat Plasma Uric Acid Reduction, Antioxidantion and Toxicity | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 93-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 劉朝鑫,王渭賢,王建雄 | |
| dc.subject.keyword | 高尿酸血症,黃嘌呤酶,抑制劑,白花水竹草,抗氧化劑, | zh_TW |
| dc.subject.keyword | hyperuricemia,xanthine oxidase inhibitor,Tradescantia albiflora Kunth,antioxidant, | en |
| dc.relation.page | 104 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2005-07-15 | |
| dc.contributor.author-college | 生物資源暨農學院 | zh_TW |
| dc.contributor.author-dept | 獸醫學研究所 | zh_TW |
| 顯示於系所單位: | 獸醫學系 | |
文件中的檔案:
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-94-1.pdf 未授權公開取用 | 2.1 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。
